1	The	the	_	_	_	_	_	_	_
2	Epstein-Barr	epstein-barr	_	_	_	_	_	_	_
3	virus	virus	_	_	_	_	_	_	_
4	oncoprotein	oncoprotein	_	_	_	_	_	_	_
5	latent	latent	_	_	_	_	_	_	_
6	membrane	membrane	_	_	_	_	_	_	_
7	protein	protein	_	_	_	_	_	_	_
8	1	1	_	_	_	_	_	_	_
9	engages	engage	_	_	_	_	_	_	_
10	the	the	_	_	_	_	_	_	_
11	tumor	tumor	_	_	_	_	_	_	_
12	necrosis	necrosis	_	_	_	_	_	_	_
13	factor	factor	_	_	_	_	_	_	_
14	receptor-associated	receptor-associated	_	_	_	_	_	_	_
15	proteins	protein	_	_	_	_	_	_	_
16	TRADD	TRADD	_	_	_	_	_	_	_
17	and	and	_	_	_	_	_	_	_
18	receptor-interacting	receptor-interacting	_	_	_	_	_	_	_
19	protein	protein	_	_	_	_	_	_	_
20	(	(	_	_	_	_	_	_	_
21	RIP	RIP	_	_	_	_	_	_	_
22	)	)	_	_	_	_	_	_	_
23	but	but	_	_	_	_	_	_	_
24	does	do	_	_	_	_	_	_	_
25	not	not	_	_	_	_	_	_	_
26	induce	induce	_	_	_	_	_	_	_
27	apoptosis	apoptosis	_	_	_	_	_	_	_
28	or	or	_	_	_	_	_	_	_
29	require	require	_	_	_	_	_	_	_
30	RIP	RIP	_	_	_	_	_	_	_
31	for	for	_	_	_	_	_	_	_
32	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
33	activation	activation	_	_	_	_	_	_	_
34	.	.	_	_	_	_	_	_	_

1	A	a	_	_	_	_	_	_	_
2	site	site	_	_	_	_	_	_	_
3	in	in	_	_	_	_	_	_	_
4	the	the	_	_	_	_	_	_	_
5	Epstein-Barr	epstein-barr	_	_	_	_	_	_	_
6	virus	virus	_	_	_	_	_	_	_
7	(	(	_	_	_	_	_	_	_
8	EBV	EBV	_	_	_	_	_	_	_
9	)	)	_	_	_	_	_	_	_
10	transforming	transform	_	_	_	_	_	_	_
11	protein	protein	_	_	_	_	_	_	_
12	LMP1	lmp1	_	_	_	_	_	_	_
13	that	that	_	_	_	_	_	_	_
14	constitutively	constitutively	_	_	_	_	_	_	_
15	associates	associate	_	_	_	_	_	_	_
16	with	with	_	_	_	_	_	_	_
17	the	the	_	_	_	_	_	_	_
18	tumor	tumor	_	_	_	_	_	_	_
19	necrosis	necrosis	_	_	_	_	_	_	_
20	factor	factor	_	_	_	_	_	_	_
21	receptor	receptor	_	_	_	_	_	_	_
22	1	1	_	_	_	_	_	_	_
23	(	(	_	_	_	_	_	_	_
24	TNFR1)-associated	tnfr1)-associated	_	_	_	_	_	_	_
25	death	death	_	_	_	_	_	_	_
26	domain	domain	_	_	_	_	_	_	_
27	protein	protein	_	_	_	_	_	_	_
28	TRADD	tradd	_	_	_	_	_	_	_
29	to	to	_	_	_	_	_	_	_
30	mediate	mediate	_	_	_	_	_	_	_
31	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
32	and	and	_	_	_	_	_	_	_
33	c-Jun	c-jun	_	_	_	_	_	_	_
34	N-terminal	n-terminal	_	_	_	_	_	_	_
35	kinase	kinase	_	_	_	_	_	_	_
36	activation	activation	_	_	_	_	_	_	_
37	is	be	_	_	_	_	_	_	_
38	critical	critical	_	_	_	_	_	_	_
39	for	for	_	_	_	_	_	_	_
40	long-term	long-term	_	_	_	_	_	_	_
41	lymphoblastoid	lymphoblastoid	_	_	_	_	_	_	_
42	cell	cell	_	_	_	_	_	_	_
43	proliferation	proliferation	_	_	_	_	_	_	_
44	.	.	_	_	_	_	_	_	_

1	We	we	_	_	_	_	_	_	_
2	now	now	_	_	_	_	_	_	_
3	find	find	_	_	_	_	_	_	_
4	that	that	_	_	_	_	_	_	_
5	LMP1	lmp1	_	_	_	_	_	_	_
6	signaling	signaling	_	_	_	_	_	_	_
7	through	through	_	_	_	_	_	_	_
8	TRADD	TRADD	_	_	_	_	_	_	_
9	differs	differ	_	_	_	_	_	_	_
10	from	from	_	_	_	_	_	_	_
11	TNFR1	tnfr1	_	_	_	_	_	_	_
12	signaling	signaling	_	_	_	_	_	_	_
13	through	through	_	_	_	_	_	_	_
14	TRADD	TRADD	_	_	_	_	_	_	_
15	.	.	_	_	_	_	_	_	_

1	LMP1	LMP1	_	_	_	_	_	_	_
2	needs	need	_	_	_	_	_	_	_
3	only	only	_	_	_	_	_	_	_
4	11	11	_	_	_	_	_	_	_
5	amino	amino	_	_	_	_	_	_	_
6	acids	acid	_	_	_	_	_	_	_
7	to	to	_	_	_	_	_	_	_
8	activate	activate	_	_	_	_	_	_	_
9	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
10	or	or	_	_	_	_	_	_	_
11	synergize	synergize	_	_	_	_	_	_	_
12	with	with	_	_	_	_	_	_	_
13	TRADD	TRADD	_	_	_	_	_	_	_
14	in	in	_	_	_	_	_	_	_
15	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
16	activation	activation	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	while	while	_	_	_	_	_	_	_
19	TNFR1	TNFR1	_	_	_	_	_	_	_
20	requires	require	_	_	_	_	_	_	_
21	approximately	approximately	_	_	_	_	_	_	_
22	70	70	_	_	_	_	_	_	_
23	residues	residue	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

1	Further	further	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	LMP1	LMP1	_	_	_	_	_	_	_
4	does	do	_	_	_	_	_	_	_
5	not	not	_	_	_	_	_	_	_
6	require	require	_	_	_	_	_	_	_
7	TRADD	TRADD	_	_	_	_	_	_	_
8	residues	residue	_	_	_	_	_	_	_
9	294	294	_	_	_	_	_	_	_
10	to	to	_	_	_	_	_	_	_
11	312	312	_	_	_	_	_	_	_
12	for	for	_	_	_	_	_	_	_
13	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
14	activation	activation	_	_	_	_	_	_	_
15	,	,	_	_	_	_	_	_	_
16	while	while	_	_	_	_	_	_	_
17	TNFR1	TNFR1	_	_	_	_	_	_	_
18	requires	require	_	_	_	_	_	_	_
19	TRADD	TRADD	_	_	_	_	_	_	_
20	residues	residue	_	_	_	_	_	_	_
21	296	296	_	_	_	_	_	_	_
22	to	to	_	_	_	_	_	_	_
23	302	302	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

1	LMP1	LMP1	_	_	_	_	_	_	_
2	is	be	_	_	_	_	_	_	_
3	partially	partially	_	_	_	_	_	_	_
4	blocked	block	_	_	_	_	_	_	_
5	for	for	_	_	_	_	_	_	_
6	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
7	activation	activation	_	_	_	_	_	_	_
8	by	by	_	_	_	_	_	_	_
9	a	a	_	_	_	_	_	_	_
10	TRADD	TRADD	_	_	_	_	_	_	_
11	mutant	mutant	_	_	_	_	_	_	_
12	consisting	consist	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	residues	residue	_	_	_	_	_	_	_
15	122	122	_	_	_	_	_	_	_
16	to	to	_	_	_	_	_	_	_
17	293	293	_	_	_	_	_	_	_
18	.	.	_	_	_	_	_	_	_

1	Unlike	unlike	_	_	_	_	_	_	_
2	TNFR1	TNFR1	_	_	_	_	_	_	_
3	,	,	_	_	_	_	_	_	_
4	LMP1	LMP1	_	_	_	_	_	_	_
5	can	can	_	_	_	_	_	_	_
6	interact	interact	_	_	_	_	_	_	_
7	directly	directly	_	_	_	_	_	_	_
8	with	with	_	_	_	_	_	_	_
9	receptor-interacting	receptor-interacting	_	_	_	_	_	_	_
10	protein	protein	_	_	_	_	_	_	_
11	(	(	_	_	_	_	_	_	_
12	RIP	RIP	_	_	_	_	_	_	_
13	)	)	_	_	_	_	_	_	_
14	and	and	_	_	_	_	_	_	_
15	stably	stably	_	_	_	_	_	_	_
16	associates	associate	_	_	_	_	_	_	_
17	with	with	_	_	_	_	_	_	_
18	RIP	RIP	_	_	_	_	_	_	_
19	in	in	_	_	_	_	_	_	_
20	EBV-transformed	ebv-transformed	_	_	_	_	_	_	_
21	lymphoblastoid	lymphoblastoid	_	_	_	_	_	_	_
22	cell	cell	_	_	_	_	_	_	_
23	lines	line	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

1	Surprisingly	surprisingly	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	LMP1	LMP1	_	_	_	_	_	_	_
4	does	do	_	_	_	_	_	_	_
5	not	not	_	_	_	_	_	_	_
6	require	require	_	_	_	_	_	_	_
7	RIP	RIP	_	_	_	_	_	_	_
8	for	for	_	_	_	_	_	_	_
9	NF-kappaB	NF-kappaB	_	_	_	_	_	_	_
10	activation	activation	_	_	_	_	_	_	_
11	.	.	_	_	_	_	_	_	_

1	Despite	despite	_	_	_	_	_	_	_
2	constitutive	constitutive	_	_	_	_	_	_	_
3	association	association	_	_	_	_	_	_	_
4	with	with	_	_	_	_	_	_	_
5	TRADD	TRADD	_	_	_	_	_	_	_
6	or	or	_	_	_	_	_	_	_
7	RIP	RIP	_	_	_	_	_	_	_
8	,	,	_	_	_	_	_	_	_
9	LMP1	LMP1	_	_	_	_	_	_	_
10	does	do	_	_	_	_	_	_	_
11	not	not	_	_	_	_	_	_	_
12	induce	induce	_	_	_	_	_	_	_
13	apoptosis	apoptosis	_	_	_	_	_	_	_
14	in	in	_	_	_	_	_	_	_
15	EBV-negative	ebv-negative	_	_	_	_	_	_	_
16	Burkitt	Burkitt	_	_	_	_	_	_	_
17	lymphoma	lymphoma	_	_	_	_	_	_	_
18	or	or	_	_	_	_	_	_	_
19	human	human	_	_	_	_	_	_	_
20	embryonic	embryonic	_	_	_	_	_	_	_
21	kidney	kidney	_	_	_	_	_	_	_
22	293	293	_	_	_	_	_	_	_
23	cells	cell	_	_	_	_	_	_	_
24	.	.	_	_	_	_	_	_	_

1	These	these	_	_	_	_	_	_	_
2	results	result	_	_	_	_	_	_	_
3	add	add	_	_	_	_	_	_	_
4	a	a	_	_	_	_	_	_	_
5	different	different	_	_	_	_	_	_	_
6	perspective	perspective	_	_	_	_	_	_	_
7	to	to	_	_	_	_	_	_	_
8	the	the	_	_	_	_	_	_	_
9	molecular	molecular	_	_	_	_	_	_	_
10	interactions	interaction	_	_	_	_	_	_	_
11	through	through	_	_	_	_	_	_	_
12	which	which	_	_	_	_	_	_	_
13	LMP1	LMP1	_	_	_	_	_	_	_
14	,	,	_	_	_	_	_	_	_
15	TRADD	TRADD	_	_	_	_	_	_	_
16	,	,	_	_	_	_	_	_	_
17	and	and	_	_	_	_	_	_	_
18	RIP	RIP	_	_	_	_	_	_	_
19	participate	participate	_	_	_	_	_	_	_
20	in	in	_	_	_	_	_	_	_
21	B-lymphocyte	B-lymphocyte	_	_	_	_	_	_	_
22	activation	activation	_	_	_	_	_	_	_
23	and	and	_	_	_	_	_	_	_
24	growth	growth	_	_	_	_	_	_	_
25	.	.	_	_	_	_	_	_	_

